Insider Buying at VBI Vaccines (VBIV) is Significant and Extends Trend of Last Quarter

Tuesday, October 31, 2017 10:15 PM ET

Insider Buying at VBI Vaccines (VBIV) is Significant and Extends Trend of Last Quarter

Compared to its peers over the last 90 days, insider buy/sell trading at VBI Vaccines is higher than the 184-company peer group average. Biotechnology & Medical Research peer group saw 210 buy/sell trades during this period for an average of 1.1 transactions per company. The number of shares per buy/sell trade for VBI Vaccines insiders was also higher. Within the peer group there were 19,292,199 shares purchased and 51,306,345 shares sold with company insiders selling 152,448 shares on average.

The data sourced in composing and writing in this story eliminates all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers.

Today’s Insider Activity
* Dr Steven Gillis, Director, bought 300,000 shares
* Sam Chawla, Director, bought 3,100,000 shares

Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.

For more information, contact UpTick at Copyright 2017 UpTick Data Technologies. All rights reserved.

This entry was posted in InsiderNews and tagged , , , , . Bookmark the permalink.